Compounds > ibuprofen
Page last updated: 2024-10-28

ibuprofen and Lung Neoplasms

ibuprofen has been researched along with Lung Neoplasms in 12 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Lung Neoplasms: Tumors or cancer of the LUNG.

Research Excerpts

ExcerptRelevanceReference
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."9.20Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
"Regular aspirin use may decrease cancer risk by reducing chronic inflammation."5.20Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015)
" This study explores the dynamics of cellular entry of dendrimers and hyperbranched polymers alone, and in the complexed form with ibuprofen, into A549 human lung epithelial carcinoma cells using UV/Vis spectroscopy, flow cytometry and fluorescence microscopy."3.72Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. ( Bassett, D; Glibatec, M; Kannan, RM; Kannan, S; Kolhe, P; Lieh-Lai, M; Raykova, V, 2004)
"Ibuprofen may inhibit lung cancer progression."2.73Factors associated with human small aggressive non small cell lung cancer. ( Berg, CD; Church, TR; Freedman, MT; Hocking, WG; Hu, P; Kvale, PA; Oken, MM; Prorok, PC; Ragard, LR; Riley, TL; Tammemagi, CM, 2007)
"3 patients in the colorectal cancer group demonstrated objective responses (1 complete remission (CR), 2 partial remission (PR))."2.68Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. ( Braun, M; Engelhardt, R; Galanos, C; Mackensen, A; Mertelsmann, R; Otto, F; Schmid, P; Seiz, A; Wehr, U, 1996)
"Ibuprofen, therefore, is a potential therapeutic agent that might allow lowering the doses of cisplatin and limiting the many challenge associated with its toxicity and development of drug resistance."1.40Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. ( Endo, H; Kido, H; Okumura, Y; Yano, M, 2014)
" Pharmacokinetic studies in rats revealed that liposome-encapsulated PIA exhibited remarkable resistance to hydrolysis by carboxylesterases, remaining largely intact in the systemic circulation, and demonstrated selective distribution to the lungs."1.40A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies. ( Alston, N; Cheng, KW; Huang, L; Mattheolabakis, G; Nie, T; Ouyang, N; Papayannis, I; Rigas, B; Wong, CC, 2014)
" These agents were tested either alone for the prevention of metastasis or in combination with IL-2 for the eradication of established metastasis."1.28Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. ( Chan, FP; Khoo, NK; Lala, PK; Saarloos, MN, 1992)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (33.33)18.2507
2000's5 (41.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Endo, H1
Yano, M1
Okumura, Y1
Kido, H1
Cheng, KW1
Nie, T1
Ouyang, N1
Alston, N1
Wong, CC1
Mattheolabakis, G1
Papayannis, I1
Huang, L1
Rigas, B1
Lang Kuhs, KA1
Hildesheim, A1
Trabert, B1
Kemp, TJ1
Purdue, MP1
Wentzensen, N1
Katki, HA1
Pinto, LA1
Loftfield, E1
Safaeian, M1
Chaturvedi, AK1
Shiels, MS1
Kannan, S2
Kolhe, P2
Raykova, V1
Glibatec, M1
Kannan, RM2
Lieh-Lai, M2
Bassett, D1
Khandare, J1
Pillai, O1
Harris, RE1
Beebe-Donk, J1
Alshafie, GA1
Tammemagi, CM1
Freedman, MT1
Church, TR1
Oken, MM1
Hocking, WG1
Kvale, PA1
Hu, P1
Riley, TL1
Ragard, LR1
Prorok, PC1
Berg, CD1
Bilodeau, JF1
Wang, M1
Chung, FL1
Castonguay, A2
Otto, F1
Schmid, P1
Mackensen, A1
Wehr, U1
Seiz, A1
Braun, M1
Galanos, C1
Mertelsmann, R1
Engelhardt, R1
Hodgson, DM1
Yirmiya, R1
Taylor, AN1
Jalbert, G1
Khoo, NK1
Chan, FP1
Saarloos, MN1
Lala, PK1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial[NCT00002540]76,685 participants (Actual)Interventional1993-11-16Active, not recruiting
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal[NCT05751837]Phase 16 participants (Anticipated)Interventional2023-03-16Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Rates From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

InterventionDeaths per 10,000 PY (Number)
Control166.6
Prostate Screening160.5

Deaths From All Causes

Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009.

InterventionParticipants (Number)
Control7089
Prostate Screening6855

Prostate Cancer Death Rates

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionDeaths per 10,000 PY (Number)
Control3.4
Prostate Screening3.7

Prostate Cancer Deaths

Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionParticipants (Number)
Control145
Prostate Screening158

Prostate Cancer Incidence

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionParticipants (Number)
Control3815
Prostate Screening4250

Prostate Cancer Incidence Rates

Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer. (NCT00002540)
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.

InterventionDiagnoses per 10,000 PY (Number)
Control97.1
Prostate Screening108.4

Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test

Number of positive screens with complications (NCT00002540)
Timeframe: One year from screening examination

InterventionPositive screens w/ complications (Number)
When DE Led to Prostate Cancer DiagnosisWhen DE Did Not Lead to Prostate Cancer Diagnosis
Prostate Screening901124

T0 (Baseline) DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T0 (at study entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening3045624811192

T0 (Baseline) PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T0 (at study entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening31507271822

T1 DRE Screening Results

Digital Rectal Examination (DRE) result. (NCT00002540)
Timeframe: T1 (one year after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening293112237900

T1 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T1 (one year after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening30159250227

T2 DRE Screening Results

Digital Rectal Examination (DRE) results (NCT00002540)
Timeframe: T2 (two years after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening283912327733

T2 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T2 (two years after entry)

InterventionParticipants (Number)
NegativePositive (> 4 ng/mL)Inadequate screen
Prostate Screening29063259335

T3 DRE Screening Results

Digital Rectal examination (DRE) result (NCT00002540)
Timeframe: T3 (three years after entry)

InterventionParticipants (Number)
NegativePositiveInadequate screen
Prostate Screening271792317748

T3 PSA Screening Results

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T3 (three years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening27814267643

T4 PSA Screening Result

Prostate-Specific Antigen (PSA) result (NCT00002540)
Timeframe: T4 (four years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening20362179612

T5 PSA Screening Results

Prostate-Specific Antigen (PSA) result. (NCT00002540)
Timeframe: T5 (five years after entry)

InterventionParticipants (Number)
Negative (<=4 ng/mL)Positive (> 4 ng/mL)Inadequate screen
Prostate Screening23560237714

Trials

3 trials available for ibuprofen and Lung Neoplasms

ArticleYear
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, Volume: 24, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete

2015
Factors associated with human small aggressive non small cell lung cancer.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10

    Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Non-Small-Cell Lung; C

2007
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Toxins; Carcinoma, Non-Small-Cell Lu

1996

Other Studies

9 other studies available for ibuprofen and Lung Neoplasms

ArticleYear
Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70.
    Cell death & disease, 2014, Jan-30, Volume: 5

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplati

2014
A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.
    International journal of pharmaceutics, 2014, Dec-30, Volume: 477, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Stability; Huma

2014
Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells.
    Journal of biomaterials science. Polymer edition, 2004, Volume: 15, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C

2004
Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload.
    Biomaterials, 2006, Volume: 27, Issue:4

    Topics: Biocompatible Materials; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Humans; Ibuprofen; Lun

2006
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
    International journal of biological sciences, 2007, Jun-13, Volume: 3, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chem

2007
Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice.
    Free radical biology & medicine, 1995, Volume: 18, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Deoxyguanosine; Dinop

1995
Intracerebroventricular interleukin-1beta impairs clearance of tumor cells from the lungs: role of brain prostaglandins.
    Journal of neuroimmunology, 2001, Sep-03, Volume: 119, Issue:1

    Topics: Adenocarcinoma; Animals; Brain; Cyclooxygenase Inhibitors; Diclofenac; Ibuprofen; Injections, Intrav

2001
Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice.
    Cancer letters, 1992, Sep-14, Volume: 66, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Carcinogens; Drug Interac

1992
Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.
    Clinical & experimental metastasis, 1992, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Animals; Cell Division; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female

1992